Edit |   |
---|---|
Antigenic Specificity | KDR/VEGFR2 (Olinvacimab biosimilar) |
Clone | monoclonal |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | IgG1 kappa lambda |
Format | Protein A/G purified |
Size | 100 µg, 1 mg, |
Concentration | typically between 0.5-2.0 mg/ml. |
Applications | ELISA, WB |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Olinvacimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting KDR/VEGFR2, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Olinvacimab is currently in phase II trials for a combination therapy to treat cancer with Merck's Keytruda. |
Immunogen | n/a |
Other Names | Olinvacimab, KDR/VEGFR2, 2095504-49-5 |
Gene, Accession # | CAS: 2095504-49-5 |
Catalog # | abx831480 |
Price | please inquire |
Order / More Info | KDR/VEGFR2 (Olinvacimab biosimilar) Antibody from ABBEXA LTD |
Product Specific References | n/a |
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950